Marico Ltd. Share Price

Bajaj consumer reaffirms fy27 growth at 15-19%.

Bajaj Consumer Care Limited

Marico buys 24.09% more of Plix for Rs 1,012.03 crore

Marico raises PLIX stake to 84% for ₹1,012 crore

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Marico Limited (

Marico invests ₹1,012 crore to raise PLIX stake

Marico raises PLIX stake to 84.09% Marico Limited (NSE: MARICO) has acquired an additional 24.09% stake in Satiya Nutraceuticals, the parent company of PLIX, for ₹1,012.03 crore. The transaction takes Marico’s ownership from 60% to 84.09% on a fully diluted basis. Key details • Marico completed the acquisition on October 5, 2026. • Its aggregate investment for the 84.09% holding now stands at ₹1,392.07 crore. • Satiya Nutraceuticals’ consolidated turnover increased to ₹864.31 crore in FY26 from ₹432.84 crore in FY25. • Marico is expected to acquire the remaining 14.09% stake in July 2027, with base consideration of up to ₹592 crore plus milestone-linked payments. My view The most interesting number is Satiya’s revenue growth. Turnover has nearly doubled in one year, which helps explain why Marico is increasing its ownership despite the sizeable ₹1,012 crore consideration. This also increases Marico’s exposure to nutrition, wellness and premium personal care, businesses that are structurally different from its traditional categories. The key question is valuation. The investment only creates value if PLIX can continue scaling while improving profitability and cash generation. What I’m watching next I will watch PLIX’s FY27 revenue growth, profitability and the final acquisition of the remaining stake in July 2027. Stance: Positive on the growth of the acquired business, but future margins and returns on the ₹1,392 crore invested so far are the key metrics to track. Disclosure: I do not have any holding or position in the stock mentioned above.

Marico Q2 FY27 update: operating profit seen up mid-20s

Marico raises Plix stake to 84% for ₹1,012 crore

Marico acquired an additional 24.09% stake in Satiya Nutraceuticals for ₹1,012.03 crore, raising its total holding to 84.09%. This secures deeper control over the high-growth digital wellness brand Plix ahead of a planned full buyout by July 2027. The transaction follows Satiya's FY26 turnover doubling to ₹864.31 crore from ₹432.84 crore in FY25. This matters because it accelerates Marico's pivot from low-margin commodity staples to high-growth, digital-first plant-based nutrition. I am watching the Q3 FY27 consolidated earnings for Plix's specific EBITDA margin contribution and the execution timeline for the final ₹592 crore tranche. The market is pricing this ₹1,012 crore outlay purely as expensive capital deployment, fixated on the premium valuation multiple. What the consensus misses is the structural multiple re-rating this enables for Marico's overall portfolio. Traditional FMCG staples trade at compressed multiples due to volume stagnation and input cost volatility. By consolidating a brand that nearly doubled its revenue in a year, Marico is actively injecting a high-velocity, digital-first growth engine into its core. My analysis shows that absorbing Plix's superior gross margins will mechanically lift the parent's blended EBITDA profile over the next four quarters. The market treats this as a standard FMCG acquisition, ignoring that it is a strategic arbitrage play to transition Marico's valuation from a legacy staple proxy to a premium wellness conglomerate. Accumulate for long-term portfolio premiumization. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice.